Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Posts 16-Percent Rise in Q3 Sales as Losses Swell 18 Percent

This update includes the fact that Cepheid ended the quarter with $82.2 million in marketable securities as well as $16.2 million in cash and equivalents.
NEW YORK (GenomeWeb News) — Cepheid today said third-quarter revenues increased 16 percent as R&D spending rose 17 percent and net loss increased 18 percent.
Total receipts for the three months ended Sept. 30 increased to $23.8 million from $20.4 million year over year.
The company said sales of clinical products were up 135 percent to $5.8 million and sales of its industrial products climbed 28 percent to $4.8 million.
However, sales in its bio-threat products fell 7 percent to $12.1 million from $13 million a year ago, which Cepheid said was partly due to the completion of contracts with the USPS.
R&D spending increased to $5.6 million from $4.8 million year over year.
The company said net losses increased to $3.9 million from $3.3 million in the year-ago period.
Cepheid said it had around $16.2 million in cash and cash equivalents and $82.2 million in marketable securities as of Sept. 30.
The company said it expects to generate between $83 million and $86 million in sales in 2006.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.